We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of CINC yet.

CINC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q1 2023, worth a combined $0 — down 100% from $461M a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of CINC and 0 opened new positions — a net loss of 102 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sofinnova Investments, exiting entirely with an estimated $74.6M sold.

  • 0 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q1 2023, down from 102 in Q4 2022.
  • Funds reported $0 of CinCor Pharma, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new CinCor Pharma, Inc. Common Stock positions in Q1 2023 and 102 closed out, a net change of -102 holders.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q1 2023 was Sofinnova Investments, an estimated $74.6M sold.

Based on aggregated 13F filings for Q1 2023.